Uncategorized
STAT+: Enliven Therapeutics’ leukemia drug shows promise in new study
A targeted drug from Enliven Therapeutics induced molecular responses in nearly half of patients with advanced leukemia, including higher response rates in patients treated at an earlier stage of their disease.
The updated early-stage study results reported Thursday for the Enliven drug, ELVN-001, compare favorably to a current blockbuster medicine sold by Novartis and an upstart experimental drug recently bought by Merck.
At 24 weeks, an 80 mg, once-daily dose of ELVN-001 achieved a major molecular response in 48% of patients with chronic myeloid leukemia, or CML, a slow-growing cancer that starts in myeloid cells.
A targeted drug from Enliven Therapeutics induced molecular responses in nearly half of patients with advanced leukemia, including higher response rates in patients treated at an earlier stage of their disease.
The updated early-stage study results reported Thursday for the Enliven drug, ELVN-001, compare favorably to a current blockbuster medicine sold by Novartis and an upstart experimental drug recently bought by Merck.
At 24 weeks, an 80 mg, once-daily dose of ELVN-001 achieved a major molecular response in 48% of patients with chronic myeloid leukemia, or CML, a slow-growing cancer that starts in myeloid cells.